PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Kolon Life Science returned to profit in 2025, but now faces a mix of steady chemical-business contribution and continued uncertainty around the TG-C (Invossa) Phase 3 program.
Full-year 2025 operating profit and net profit turned positive after two consecutive years of losses.
TG-C's first US Phase 3 trial (study 15302) failed to reach statistical significance versus placebo.
Top-line results for the second Phase 3 trial (study 12301) were postponed from October to December.
Quarterly earnings swing sharply relative to revenue, largely due to non-recurring items.
The criminal case tied to Invossa ended in a final acquittal, but civil litigation risk remains.
Kolon Life Science operates on two pillars: a precision-chemicals (chemical) business handling active pharmaceutical ingredients (API) and functional materials, and a biotech business developing gene and cell therapies.
The chemical division includes an SC business supplying eco-friendly antimicrobial agents to global customers and securing stable demand in personal-care and marine anti-fouling coating markets, and it has historically accounted for the overwhelming majority of consolidated revenue, acting as the company's cash cow.
The core of the biotech business is 'Invossa' (TG-C), developed as the world's first cell-and-gene therapy for osteoarthritis; Kolon Life Science holds domestic and Asian rights and owns a 14.8% stake in affiliate Kolon TissueGene, which holds US and European rights and leads development and manufacturing.
In April 2022 the company signed a license-out agreement with Singapore-based Juniper Biologics covering TG-C rights in certain regions outside Asia.
Beyond Invossa, the company is advancing follow-on pipeline candidates KLS-2031, a neuropathic pain gene therapy, and KLS-3021, an oncology gene therapy, both of which are at the stage of exploring licensing opportunities with global pharmaceutical partners.
Biomanufacturing infrastructure is handled by Kolon Biotech, a subsidiary spun off in 2020, and the company is reportedly discussing cooperation with contract development and manufacturing partners such as Switzerland's Lonza in preparation for TG-C commercialization.
That said, the biotech segment's revenue contribution remains limited, with one report noting the segment accounted for only about 1% of sales as of 2024.
Competitively, the chemical division competes on price and quality against numerous specialty-chemical peers, while TG-C occupies a rarer competitive position globally as a cell-and-gene therapy approach to osteoarthritis.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩53B | ₩1.3B | 2.4% |
| 2025Q3 | ₩66.5B | ₩18.9B | 28.4% |
| 2025Q4 | ₩44.7B | -₩2.7B | −6.0% |
| 2026Q1 | ₩49.7B | ₩2.9B | 5.9% |
| 2026Q2 | ₩50.6B | -₩800M | −1.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩192.4B | ₩1.6B | ₩2.1B | 0.8% | 1.3% | 87.3% |
| 2023 | ₩124.6B | -₩24.1B | -₩30.7B | −19.3% | −22.3% | 124.8% |
| 2024 | ₩161.4B | -₩22.1B | -₩93.1B | −13.7% | −62.3% | 180.9% |
| 2025 | ₩209B | ₩17.6B | ₩25B | 8.4% | 4.3% | 56.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Revenue fell from KRW 192.4 billion in 2022 to KRW 124.6 billion in 2023, then rose for two straight years to KRW 161.4 billion in 2024 and KRW 209.0 billion in 2025.
Operating profit swung from a KRW 1.6 billion surplus in 2022 to losses of KRW 24.1 billion in 2023 and KRW 22.1 billion in 2024, before turning positive again in 2025 at KRW 17.6 billion, an 8.4% operating margin.
Net profit attributable to owners followed a similar path, posting large losses of KRW 30.7 billion in 2023 and KRW 93.1 billion in 2024 before turning to a KRW 25.0 billion profit in 2025.
The large 2024 net loss reflects a combination of one-off factors, including a revenue gap from the discontinuation of the water-treatment (WS) business, a fire at the Gimcheon No.2 plant, and provisions set aside for investor damages litigation related to Invossa.
On a quarterly basis, operating profit jumped to KRW 18.9 billion in the third quarter of 2025 against revenue of only KRW 66.5 billion for the same quarter, producing an unusually high margin—likely reflecting one-off gains tied to the June 2025 transfer of comprehensive MPPO-related technology and rights to Kolon Industries.
The fourth quarter of 2025 reverted to losses, with revenue of KRW 44.7 billion, an operating loss of KRW 2.7 billion and a net loss of KRW 9.6 billion, while the first quarter of 2026 posted a modest operating profit of KRW 2.9 billion on revenue of KRW 49.7 billion but a much larger owners' net profit of KRW 20.8 billion, suggesting a significant non-operating contribution.
The second quarter of 2026 swung back to losses, with revenue of KRW 50.6 billion, an operating loss of KRW 0.8 billion and a net loss of KRW 2.2 billion.
Taken together, the most recent four quarters (Q3 2025 through Q2 2026) show earnings direction flipping sharply from quarter to quarter, indicating an earnings structure driven more by non-recurring items than by stable operating cash generation.
The osteoarthritis (OA) treatment market remains a prominent area of unmet medical need, as no disease-modifying osteoarthritis drug (DMOAD) has yet been approved. Market researcher ResearchNester projected the global osteoarthritis treatment market to expand from roughly USD 10.8 billion to USD 36.6 billion by 2035.
TG-C has drawn attention as the world's first cell-and-gene therapy candidate for osteoarthritis, and with no FDA-approved DMOAD-class therapy yet in existence, successful development could offer a first-mover advantage.
However, the July 2026 top-line results from TG-C's first US Phase 3 trial (study 15302) confirmed pain relief and functional improvement but failed to reach statistical significance versus placebo, again highlighting the clinical difficulty of osteoarthritis drug development, particularly in managing placebo response.
The API and precision-chemicals market the company also operates in is a relatively mature industry, with a comparatively stable demand base built on supplying antimicrobial agents and functional materials to global customers.
Korea's KOSDAQ pharmaceutical and biotech sector tends to see share prices react sharply to individual clinical and regulatory events, and Kolon Life Science has similarly shown elevated volatility tied to TG-C news flow.
Global big pharma companies have also attempted osteoarthritis drug development without any regulatory approval to date, a fact that positions the outcome of the Kolon group's program as a potential industry benchmark.
Kolon TissueGene released top-line results for TG-C's first US Phase 3 trial (study 15302) on July 20, 2026, but the primary endpoints failed to reach statistical significance versus placebo. The company attributed this largely to a stronger-than-expected placebo effect and has begun a root-cause analysis.
Top-line results for the second Phase 3 trial (study 12301), originally scheduled for October, were postponed to December to allow a more thorough combined analysis.
The company plans to reset its Biologics License Application (BLA) timeline in consultation with the FDA after the second trial's results are available, and has indicated the originally targeted second-half-2028 commercialization schedule could be pushed back as a result.
The company has also left open the possibility of conducting an additional clinical trial, meaning meaningful time and uncertainty remain before TG-C could reach final approval and commercialization.
Separately, Kolon Life Science is pursuing licensing discussions with global pharmaceutical partners for its neuropathic pain candidate KLS-2031 and oncology gene therapy KLS-3021, with industry observers noting that a tangible deal in either program ahead of TG-C's commercialization could provide near-term cash inflow and business diversification.
The chemicals business is expected to continue contributing steadily on the back of its global customer base for antimicrobial agents and functional materials, with regulatory progress such as Japanese PMDA approval in the pharmaceutical business offering further potential upside to results.
Kolon Life Science's share price has reacted sharply to both the 2025 return to profit and TG-C-related news flow, and the price-to-earnings ratio calculated on the most recent four quarters of results looks markedly lower than during the prior loss-making years.
However, a substantial portion of net profit over this window stems from one-off items such as technology and rights transfers, so it should be interpreted differently from earnings generated purely by ordinary operations.
The metric relating share price to net assets sits in a range below net asset value, suggesting the market retains a cautious view on the sustainability of future earnings.
The company has not been paying a cash dividend recently, so dividend appeal plays little role, leaving the progress of TG-C's clinical and regulatory pathway and any licensing outcomes for follow-on pipeline assets as the key variables driving the share price.
The durability of the earnings turnaround and the outcome of the biotech pipeline are likely to remain the central variables for any future valuation reassessment.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
The return to a KRW 209.0 billion revenue and KRW 17.6 billion operating profit in 2025 was underpinned by a stable demand base in the chemicals business supplying antimicrobial agents and functional materials.
Regulatory progress in the pharmaceutical business, such as a Japanese PMDA approval, could also support results going forward. The chemicals business provides a cash-generation base independent of clinical uncertainty in the biotech segment.
Beyond TG-C, the company is nurturing follow-on candidates KLS-2031 for neuropathic pain and KLS-3021 for oncology, and is exploring licensing deals with global pharmaceutical partners.
Industry observers note that a deal in either program ahead of TG-C's commercialization could contribute near-term cash inflow and business diversification. This reduces reliance on a single asset, TG-C.
Criminal proceedings against executives and employees indicted over the Invossa ingredient controversy resulted in acquittals at both the first and second trial levels, and prosecutors' decision not to appeal further made the acquittal final.
This is seen as resolving a substantial portion of legal uncertainty that had persisted for more than five years. The removal of this criminal-law risk improves stability for executing future management strategy.
TG-C's first US Phase 3 trial (study 15302), reported in July 2026, showed pain and function improvement but failed to reach statistical significance versus placebo on its primary endpoint.
The company pointed to an unusually strong placebo effect as the cause, but identifying the root cause and resetting the commercialization timeline will take time. Top-line results for the second Phase 3 trial were also postponed from October to December, extending the uncertainty.
Certain quarters, such as an operating profit of KRW 18.9 billion in the third quarter of 2025 and an owners' net profit of KRW 20.8 billion in the first quarter of 2026, showed profit levels disproportionate to revenue size on a recurring basis.
This is presumed to reflect one-off items such as technology and rights transfers, making it difficult to read as a signal of stable operating profitability. Conversely, the fourth quarter of 2025 and second quarter of 2026 swung back into losses, underscoring large quarter-to-quarter variance.
One report noted the biotech business accounted for only about 1% of revenue as of 2024, meaning results still depend heavily on the chemicals segment.
Additional clinical and regulatory steps and time are required before TG-C can be commercialized, making it difficult for the biotech segment to substantially increase its revenue contribution in the near term. This creates a gap between the pipeline's potential future value and the company's current revenue structure.
Results for the second Phase 3 trial (study 12301) are due in December, but the possibility that it also fails to reach statistical significance, as the first study did, cannot be ruled out.
The company plans to reset its BLA filing timeline in consultation with the FDA after the results are released, but the outcome of that consultation could require an additional clinical trial. In that scenario, the commercialization timeline could be delayed further beyond the original target.
While the criminal case over the Invossa ingredient issue ended in a final acquittal, separate civil damages lawsuits filed by investors are ongoing, and a first-instance ruling favored the plaintiffs. In response, the company has previously recognized provisions related to such litigation. Depending on the outcome of these ongoing suits, additional financial burden could arise.
A significant portion of the 2025 earnings improvement is presumed to stem from intra-group transactions such as the MPPO-related technology and rights transfer to Kolon Industries.
The company also holds a 14.8% stake in Kolon TissueGene, which owns TG-C's US and European rights, meaning equity-method gains or losses could be linked to the affiliate's performance and clinical outcomes. This dependence on affiliate-driven profit and loss reduces the predictability of results.
Top-line results for TG-C's second US Phase 3 trial (study 12301) are due, with the key question being whether it can overturn the first study's failure to reach statistical significance.
The third-quarter results should be checked for whether chemicals-segment profitability persists and whether one-off gains or losses recur.
Progress on global licensing negotiations for KLS-2031 and KLS-3021 could serve as a near-term catalyst for biotech diversification.
Following the second trial results, it will be important to track the outcome of BLA-timeline discussions with the FDA and any resulting changes to the commercialization target date.
Kolon Life Science turned all of revenue, operating profit, and net profit positive in 2025, prompting views that the earnings trough had passed, but behind this lies not only a stable contribution from the chemicals segment but also a significant influence from one-off items such as technology and rights transfers.
The core growth driver, TG-C (Invossa), failed to reach statistical significance versus placebo in its first US Phase 3 trial reported in July 2026, and the postponement of second-trial results to December has increased uncertainty around the commercialization timeline.
The criminal-law risk tied to Invossa has been resolved with a final acquittal, though some legal burden remains in the form of ongoing investor damages litigation. Whether follow-on pipeline assets KLS-2031 and KLS-3021 secure licensing deals stands out as a potential variable that could offset TG-C-related risk.
Quarterly results show a structure where profit and loss swing widely regardless of revenue scale, meaning future results should be examined by distinguishing one-off items from recurring operating performance.
On balance, the company combines a stable chemicals business base with a biotech pipeline carrying substantial uncertainty, and the December clinical results together with any follow-on pipeline deals remain the key variables that will shape its future direction.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.